{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:48:38Z","timestamp":1791143318673,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.urology.2003.11.031","type":"journal-article","created":{"date-parts":[[2004,5,8]],"date-time":"2004-05-08T08:09:36Z","timestamp":1084003776000},"page":"989-993","source":"Crossref","is-referenced-by-count":27,"title":["Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY"],"prefix":"10.1016","volume":"63","author":[{"given":"Jun","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kakehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2003.11.031_BIB1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0022-5347(05)66440-3","article-title":"Cystectomy for bladder cancer","volume":"165","author":"Dalbagni","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2003.11.031_BIB2","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(02)00930-0","article-title":"The role of systemic chemotherapy in the management of muscle-invasive bladder cancer","volume":"3","author":"Juffs","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2003.11.031_BIB3","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2001.19.20.4005","article-title":"Integrated therapy for locally advanced bladder cancer","volume":"19","author":"Millikan","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2003.11.031_BIB4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2174\/0929867033457872","article-title":"Noninvasive molecular detection of cancer\u2014the bench and the bedside","volume":"10","author":"Goessl","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.urology.2003.11.031_BIB5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1126\/science.2024123","article-title":"Identification of p53 gene mutations in bladder cancers and urine samples","volume":"252","author":"Sidransky","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.urology.2003.11.031_BIB6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.urology.2003.11.031_BIB7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004410051072","article-title":"Predicting response to cancer chemotherapy","volume":"292","author":"Weller","year":"1998","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.urology.2003.11.031_BIB8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0022-5347(01)62747-2","article-title":"Prognostic markers in bladder cancer","volume":"160","author":"Stein","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2003.11.031_BIB9","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJM199411103311903","article-title":"Accumulation of nuclear p53 and tumor progression in bladder cancer","volume":"331","author":"Esrig","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2003.11.031_BIB10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1054\/bjoc.2001.1823","article-title":"p53 mutations in urinary bladder cancer","volume":"84","author":"Berggren","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2003.11.031_BIB11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/(SICI)1097-0215(19960729)67:3<447::AID-IJC22>3.0.CO;2-3","article-title":"Clonarity and stability of the p53 gene in human astrocytic tumor cells","volume":"67","author":"Tada","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urology.2003.11.031_BIB12","first-page":"171","article-title":"Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods","volume":"8","author":"Lu","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2003.11.031_BIB13","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1073\/pnas.92.9.3963","article-title":"A simple p53 functional assay for screening cell lines, blood, and tumors","volume":"92","author":"Flaman","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.urology.2003.11.031_BIB14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1525-1578(10)60629-0","article-title":"Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay","volume":"2","author":"Duddy","year":"2000","journal-title":"J Mol Diag"},{"key":"10.1016\/j.urology.2003.11.031_BIB15","first-page":"199","article-title":"Urological tumours, in Sobin LH, and Wittekind CH (Eds):TNM Classification of Malignant Tumours","author":"Sobin","year":"2002"},{"key":"10.1016\/j.urology.2003.11.031_BIB16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jjco\/28.8.497","article-title":"Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma","volume":"28","author":"Kuroda","year":"1998","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urology.2003.11.031_BIB17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1349-7006.1998.tb00551.x","article-title":"Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas","volume":"89","author":"Kakehi","year":"1998","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.urology.2003.11.031_BIB18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jnci\/85.1.53","article-title":"Detection of p53 mutations in superficial (T1) bladder carcinomas as a marker of disease progression","volume":"85","author":"Sarkis","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2003.11.031_BIB19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/01.ju.0000056085.58221.80","article-title":"The p53 tumor suppressor gene and nuclear protein","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2003.11.031_BIB20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jnci\/88.3-4.173","article-title":"The p53 gene in breast cancer","volume":"88","author":"Sj\u00f6gren","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2003.11.031_BIB21","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/sj.onc.1201374","article-title":"Loss of function and p53 protein stabilization","volume":"15","author":"Blagosklonny","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.urology.2003.11.031_BIB22","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/bjc.1998.371","article-title":"Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder","volume":"77","author":"Abdel-Fattah","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2003.11.031_BIB23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000055316","article-title":"Evaluation of methods to detect p53 mutations in ovarian cancer","volume":"60","author":"Meinhold-Heerlein","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.urology.2003.11.031_BIB24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/(SICI)1097-0045(19991001)41:2<134::AID-PROS8>3.0.CO;2-E","article-title":"Use of a yeast assay to detect functional alterations in p53 in prostate cancer","volume":"41","author":"deVerre White","year":"1999","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2003.11.031_BIB25","first-page":"4452","article-title":"Dominant negative effect of a germ-line mutant p53","volume":"53","author":"Srivastava","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2003.11.031_BIB26","first-page":"4765","article-title":"Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme","volume":"59","author":"Marutani","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2003.11.031_BIB27","first-page":"600","article-title":"Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay","volume":"7","author":"Okuda","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2003.11.031_BIB28","first-page":"5572","article-title":"p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas","volume":"59","author":"Hashimoto","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2003.11.031_BIB29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/385123b0","article-title":"p53 and treatment of bladder cancer","volume":"385","author":"Cote","year":"1997","journal-title":"Nature (Lond)"},{"key":"10.1016\/j.urology.2003.11.031_BIB30","first-page":"3500","article-title":"TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer","volume":"5","author":"Qureshi","year":"1999","journal-title":"Clin Cancer Res"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429503013256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429503013256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T17:20:40Z","timestamp":1549732840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429503013256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0090429503013256"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2003.11.031","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}